For the full year 2015, Goettingen, Germany-based biopharma vendor Sartorius reported sales of €1.1bn ($1.2bn), 16% higher than the previous year. The bulk of this - €809m- came from the firm’s Bioprocess Solutions Division, itself growing 21% year-on-year.
“In 2015, our growth driver was the Bioprocess Solutions Division yet again,” said Dr. Joachim Kreuzburg, who added the firm operates “in an exceptionally dynamic market where we also gained further share.”
Much of the growth within the Bioprocess Solutions business was attributed to demand for single-use products, which the firm said “was especially high” across all regions.
In the third quarter, the company found uptake from the US was a particularly strong factor, echoing a BCC Research Report predicting the region would catch-up and overtake Europe in its adoption of single-use technologies over the next few years.
Sartorius also attributed much of its growth to its recent M&A activity, which has seen the addition and integration of cell line and process development contractor Cellca GmbH and contract testing firm BioOutsource, over the past 12 months.
“These two companies also grew significantly and contributed nearly two percentage points in constant currencies to the division's sales expansion,” Sartorius said.
Going forward, the company also reported a sharp rise in order intake, up 23% to €870m.